Truist upgraded Gilead (GILD) to Buy from Hold with a price target of $127, up from $108, after the company beat Q2 expectations for sales and EPS, driven by the HIV segment. Strength in HIV also prompted a guidance raise guidance, notes the analyst, who is “highly encouraged” by the leading indicators of demand for Yeztugo. Cell therapy continues to face challenges, but the firm thinks this will be “invigorated” with Anito-cel, while it continues to think Gilead has a “best-in-class, unparalleled HIV business,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating
- Gilead Sciences Reports Strong Q2 2025 Results
- Gilead Sciences: Strong Financial Performance and Positive Outlook Justify Buy Rating
- Closing Bell Movers: Expedia, TripAdvisor jump on Q2 earnings beats
- Gilead reports Q2 EPS $2.01, consensus $1.96